ImmunoGen: Experiencing Big Internal Changes
June 28, 2019
0
ImmunoGen’s Big Internal Changes ImmunoGen (IMGN) announced a radical impacting decision following the completion of an in-depth operational review aimed at extending the Company’s cash runway; delivering on its promises to continue developing a promising antibody drug conjugate (ADC) product and moving into the clinic what it believes will be next-generation ADCs. Based on the outcomes of its review, ImmunoGen prioritized continuing the development of mirvetuximab and …